NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Inclusion Criteria: * Be able to understand and sign the Informed of Consent Document. Be willing to follow the procedure and protocol of the clinical trial; * Age ≥ 18 years and ≤ 70 years; * Expected survival time \> 3 months; * ECOG score 0-1; * Metastatic or recurrent solid tumors confirmed by histopathology; * Refractory to standard treatment evaluated by radiological assessment; * Be able provide fresh or preserved tissue specimen; * At least 1 measurable lesion (according to RECIST 1.1); * NY-ESO-1 expression positive: Immunohistochemical staining positive cells ≥25% and positive staining intensity is "++" or above; * HLA typing is HLA-A2 (excluding HLA-A\*0203); * Hematology should at least meet the following criteria: 1. Absolute neutrophil count (ANC) ≥ 1.5× 109/L (±20%)； 2. Platelet (PLT） ≥ 75× 109/L (±20%）； 3. Hemoglobin (HGB) ≥ 90 g/L (±20%). * Liver and kidney function are normal: 1. Serum creatinine (Cr) ≤ 1.5 times of upper limit of normal (ULN) or creatine clearance ≥ 60 ml/min; 2. Serum Alanine aminotransferase (ALT) or/and Aspartate aminotransferase (AST) ≤ 2.5 times of upper limit of normal; 3. Total bilirubin (TBIL) ≤ 15 times of upper limit of normal. * Blood coagulation function is normal: Prothrombin time (PT) ≤ 1.5 ULN, International Normalized Ratio (INR) ≤ 1.5 ULN, or Activated Partial Thromboplastin Time (APTT) ≤ 1.5 ULN; * Echocardiogram results show: Left ventricular ejection fraction \>45%; * Women of childbearing potential should be ascetic or take contraception since the signing of ICF to 24 weeks or later after the last administration of drug Note: Women of childbearing age who have undergone surgical sterilization or who have already experienced menopause are considered to have no possibility of pregnancy. * Before the TC-N201 injection was reconstituted, the toxic effects of standard treatment had already recovered, and the corresponding adverse events were judged by the researcher to not pose a safety risk; * Catheter insertion is feasible and No White Blood Cells collection contraindications. Exclusion Criteria: * Under pregnancy or lactation, or positive based on blood pregnancy test; * Severe allergic to related ingredients in the clinical trial; * Received any other investigational treatment within 4 weeks before the first administration or enrolled in another clinical trial the same time; * History of other known malignant tumors within the previous 5 years, including carcinoma in situ of the cervix, basal cell carcinoma of the skin, and carcinoma in situ of the prostate; Except for localized tumors that have been cured; * Primary central nerve system (CNS) cancer, or subjects with CNS metastasis after localized treatment; * Subjects with any active autoimmune disease, a history of autoimmune disease, or a history or syndrome requiring treatment with systemic steroids or immunosuppressive drugs; * Immunodeficiency including HIV positive, harvested or natural immunodeficiency; * Subjects with ≥ grade 3 thromboembolic events within 2 years or under thrombolysis treatment; * Subjects with hereditary or acquired hemorrhagic disease; * Have clinical cardiovascular disease or symptoms; * Subjects with active infection: active infection requiring systemic anti-infective treatment (except topical antibiotics), fever caused by cancer could be enrolled according to the investigator's judgment; * Subjects with active pulmonary tuberculosis infection detected by medical history or Computed Tomography (CT), or a history of active pulmonary tuberculosis infection within 1 year before enrollment, or a history of active pulmonary tuberculosis infection more than 1 year before enrollment but without regular treatment; * Subjects with positive hepatitis B surface antigen or positive hepatitis B core antibody or positive hepatitis C virus antibody; * Treponema pallidum antibody positive; * Subjects received major surgery or under severe injury within 4 weeks before TC-N201 cell infusion; * Subjects who received live vaccine or attenuated live vaccine 28 days before leukapheresis; * Subjects who have drug addiction history, or alcoholism, drug users; * Subjects who received cell therapy before enrollment，such as TCR-T，CAR-T and TIL; * Subjects who have previously received treatment targeting NY-ESO-1; * Subjects not suitable for the clinical trial according to investigators.